

Age, Comorbidities, and AIDS Predict a Frailty Phenotype in Men Who Have Sex With Men

Keri N. Althoff,¹ Lisa P. Jacobson,¹ Ross D. Cranston,² Roger Detels,³ John P. Phair,⁴ Xiuhong Li,¹ and Joseph B. Margolick⁵; for the Multicenter AIDS Cohort Study (MACS)

¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

²Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania.

³Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.

⁴Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

⁵Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Address correspondence to Keri N. Althoff, PhD, MPH, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Rm E7142, Baltimore, MD 21205. Email: kalthoff@jhsph.edu

Background. Adults aging with HIV infection are at risk for age-related comorbidities and syndromes, such as frailty. The objective of this study was to evaluate the expression and predictors of the frailty phenotype (FP) among HIV-infected (HIV+) and HIV-uninfected (HIV-) men who have sex with men.

Methods. A prospective, observational cohort study was nested in the Multicenter AIDS Cohort Study from October 2007–September 2011. FP conversion was defined as the onset of FP over two consecutive study visits. Adjusted odds ratios and 95% confidence intervals (CI) for FP conversion were estimated using logistic regression models with generalized estimating equations.

Results. Of 10,571 completed study visits from 1,946 men who have sex with men, 12% and 9% were FP+ among HIV+ and HIV- men, respectively ($p = .002$). The proportion of FP+ visits increased with age regardless of HIV status, but was significantly greater in HIV+ compared to HIV- men aged 50–64 years. Of the 10,276 consecutive visit pairs contributed by participants, 5% (537) were classified as FP conversion, and 45% of the men with FP conversion had only one FP+ study visit. FP conversion was significantly associated with a history of AIDS (adjusted odds ratios = 2.26 [1.50, 3.39], but not with HIV+ alone (adjusted odds ratios = 1.26 [0.98, 1.64]). Among men who had one or more FP+ visits, 34% of HIV+ and 38% of HIV- men had less than two comorbidities.

Conclusions. These findings suggest that expression of the FP can be measured in men who have sex with men with and without HIV infection and reflects multisystem dysfunction in this population; further investigations are needed to better understand clinical utility.

Key Words: Epidemiology—Frailty—Multimorbidities.

Received May 14, 2013; Accepted July 24, 2013

Decision Editor: Stephen Kritchevsky, PhD

INTRODUCTION

The proportion of Americans living with HIV infection (HIV+) who are older than 50 years is increasing, due to both increased survival from effective antiretroviral treatment (1,2) and incident infections in persons aged 50 and older, estimated at 5,500/y or 10.8% of all new infections in the U.S. (3). In the 40 states with confidential name-based reporting, it was estimated that 31% of HIV+ persons were age 50 years or older in 2008 (4). This proportion is expected to exceed 50% by 2015 (5).

Frailty is an aging-related condition characterized by increased vulnerability to stressors, thought to be due to multisystem dysregulation (6–14). Frailty manifests clinically as a decrease in muscle mass, energy, weight,

physical strength, and physical activity (7,8,15). The most widely used frailty phenotype (FP) was defined by Fried and colleagues (7), in a population of older (65–101 years), presumably HIV-uninfected (HIV-) adults, and requires the presence of three or more of five criteria: weakness, slowness, unintentional weight loss, low energy, and low physical activity. This FP has been validated as a clinical syndrome in elderly populations, and its presence predicts loss of independence, disability, falls, and death (6,7,16–20).

As more and more HIV+ individuals receiving antiretroviral therapy are developing non-AIDS-defining diseases that have traditionally been associated with aging (21–25), it is important to understand the effects of HIV and of

antiretroviral therapy on the physiology and manifestations of aging. To begin to address these questions, the Multicenter AIDS Cohort Study (MACS) defined a frailty-related phenotype (FRP) that approximated the FP using existing data. The FRP was defined as expression of at least three of the following four components: physical shrinking, exhaustion, slowness, and low physical activity level. The FRP differed from the FP by containing a self-reported measure of slowness, and no measure of weakness (26). Nonetheless, studies using this FRP in the MACS showed: (a) expression of the FRP was positively associated with duration of HIV infection in the absence of highly active antiretroviral therapy (HAART) (26); (b) lower CD4 T-cell counts were independently associated with expression of the FRP after accounting for use of HAART (27); and (c) expression of the FRP prior to HAART initiation independently predicted risk of AIDS or death after HAART initiation (28). However, these studies were limited because they used the FRP, rather than the validated FP, and because they could not fully adjust for the effect of other age-related comorbidities and adverse health conditions such as hepatitis C. Additionally, if frailty is an indicator of vulnerability to stressors in the HIV+ adults, and if HIV+ adults have a greater burden of frailty than HIV- adults, then HIV+ adults would be likely to have a greater burden of negative clinical outcomes as they age. Therefore, to examine the relationship of frailty and aging with HIV in more detail, in 2007 the MACS began assessing all five components of the FP at each study visit for all participants. Here, we report (a) the prevalence of the FP in the MACS, by age and HIV status; (b) predictors of conversion to the FP; and (c) the concordance of the FP with the presence of two or more comorbidities.

METHODS

Study Population

The MACS is an ongoing, prospective, interval cohort study of the natural and treated histories of HIV infection. It enrolled 4,954 HIV+ and HIV- men who have sex with men (MSM) in 1984–1985, 668 in 1987–1991, and 1,350 in 2001–2003 in four U.S. cities (Baltimore, Chicago, Los Angeles, and Pittsburgh). Study visits are semiannual and include a standardized interview, physical examination, questionnaires (including the self-administered short form-36 quality-of-life questionnaire (29,30) and items of the Centers for Epidemiologic Studies Depression Scale) (31), and collection of blood for laboratory testing and storage in local and national repositories (32). Additional details of MACS methods have been published (33–35). Study design and questionnaires are available at <http://www.statepi.jhsph.edu/mac/mac.html>. Informed consent was obtained from all study participants. The institutional review boards at each study site approved this study.

MACS participants were included in this study if they completed at least one study visit between October 1, 2007

and September 30, 2011; analyses of conversion to frailty were restricted to men who completed two study visits during this time. HIV+ men who had never received antiretroviral therapy as of October 1, 2007 were excluded to restrict the study to treatment-experienced men.

Conversion to the FP

The FP defined by Fried and colleagues (7), requires the presence of three or more of the following five components: (a) weakness (present if grip strength measured using a dynamometer is less than 20th percentile of HIV- men); (b) slowness (present if time to walk 4 m is more than 80th percentile of HIV- men); (c) unintentional weight loss (present if participant answers “yes” to the question “Since your last visit, have you had unintentional weight loss of at least 10 pounds?”); (d) exhaustion (present if participant answers “yes” to the question “During the past 4 weeks, as a result of your physical health, have you had difficulty performing your work or other activities (for example, it took extra effort?)”); and (e) low physical activity (present if participant answers “yes, limited a lot” to the question “Does your health now limit you in vigorous activities, such as running, lifting heavy objects, participating in strenuous sports?”). These measures were standardized across study sites and were collected at each MACS study visit beginning October 1, 2007; our study period was from October 1, 2007 to September 30, 2011.

Men who did not meet the criteria for the FP at a given study visit (FP-) but did meet these criteria at their next visit (FP+) were classified as having FP conversion. Two consecutive visits were used as the unit to examine predictors of FP conversion among participants. Each two-visit pair was defined as two consecutive study visits (v_i and v_{i+k}), regardless of missed visits (eg, v_i and v_{i+1} , v_{i+1} and v_{i+2} , v_{i+2} and v_{i+3} for an individual with no missing study visits, and v_i and v_{i+2} , v_{i+2} and v_{i+3} for an individual missing visit v_{i+1}). FP converters were compared with individuals without the FP at both visits in the consecutive visit pair.

Predictors of Conversion to the FP

Date of birth, race, and education were self-reported at enrollment into the MACS. Cigarette smoking and injection drug use were all self-reported at every MACS study visit.

Comorbidities were measured at every study visit during the study period. Hepatitis C infection was defined as detectable hepatitis C RNA in serum; all others were considered uninfected. Depressive symptoms were defined as a Centers for Epidemiologic Studies Depression Scale score greater than 16 (31). High blood pressure was defined as systolic pressure greater than 140 mmHg or diastolic pressure greater than 90 mmHg. Diabetes mellitus was defined as a fasting glucose greater than or equal to 126 mg/dL or a

self-report of previous clinical diagnosis with use of medication. Dyslipidemia was defined as either a fasting total cholesterol greater than or equal to 200 mg/dL, low-density lipoprotein greater than or equal to 130 mg/dL, high-density lipoprotein less than 40 mg/dL, triglycerides more than or equal to 150 mg/dL, or use of lipid-lowering medications with self-report of a previous clinical diagnosis. Kidney disease was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m² body surface area using the Modification of Diet in Renal Disease equation (36) or a urine protein-to-creatinine ratio greater than or equal to 200 mg protein/1 g creatinine. Cancer was defined as diagnosis at, or within a year of, the study visit; 97.4% of cancer diagnoses were medically confirmed.

HIV serostatus was assessed at every visit for HIV- men and positivity determined by a positive ELISA confirmed by Western blot. T-lymphocyte subsets were measured at each MACS center using standardized flow cytometry (37). Plasma HIV RNA concentrations (viral load) were measured using either the standard reverse transcription polymerase chain reaction assay (limit of detection = 400 copies/mL; Roche Diagnostics, Nutley, NJ) or with the Roche ultrasensitive assay (limit of detection = 50 copies/mL; Roche Diagnostics). HAART was defined according to the U.S. Department of Health and Human Services Kaiser Panel guidelines (38) as three or more antiretroviral drugs including either: (a) a protease inhibitor; (b) a nonnucleoside reverse transcriptase inhibitor; (c) an entry or integrase inhibitor; or (d) three nucleoside reverse transcriptase inhibitors, including abacavir or tenofovir. A history of clinical AIDS was defined as the occurrence of a clinical AIDS diagnosis (per the Centers for Disease Control and Prevention's 1993 definition, but excluding a CD4 T-cell count >200 cells/mm³) (39) occurring at or before the time of frailty assessment.

Statistical Analysis

The significance of differences in proportions and medians was determined using the chi-square test and the Kruskal-Wallis test, respectively. For analyses of study visits (as opposed to participants), participants could contribute data from multiple study visits; statistical comparisons were made using generalized linear models with generalized estimating equations that included an independent working correlation matrix to take into account repeated measures from individuals (log link with binomial variance was specified for differences in categorical variables). The intraclass correlation coefficient was used to determine the proportion of the variability that was attributable to differences between study participants (as opposed to the variability within an individual in a repeated measures setting).

Predictors of conversion to the FP were measured at all study visits during the study period; predictors measured at the first visit of each consecutive visit pair were used in the

models, with the exception of race, education, and study center, which were measured once at the time of enrollment into the MACS. Predictors with face validity and/or statistically significant univariate associations were included in multivariate models. Logistic regression models with generalized estimating equations (40) were used to estimate the odds of FP conversion for the selected predictors.

The concordance between FP+ status and having two or more comorbidities was determined by estimating the proportion of men with FP+ status at the first visit who had two or more comorbidities (7).

A *p* value less than .05 guided statistical interpretation, and all analyses were completed using SAS version 9.2 (SAS Institute, Cary, NC).

RESULTS

The study population consisted of 1,946 men (898 HIV+ and using HAART and 1,048 HIV-) who completed at least one study visit between October 1, 2007 and September 30, 2011. These men contributed 10,571 visits (4,842 from HIV+ men and 5,729 from HIV- men). The median number of visits per participant was six (interquartile range: 4, 7) for both HIV+ and HIV- men (*p* = .76). Twenty-two percent of HIV+ men and 21% of HIV- men completed all eight possible study visits (*p* = .29).

Prevalence and Durability of the FP

Of the 1,946 men studied, 1,469 (75%) were FP- at all visits contributed, and 477 (25%) were FP+ at one or more visits (Table 1). The latter were older and more likely to be HIV+ or non-Hispanic black, and of lower educational attainment (Table 1). The HIV+ men were more likely to have at least one FP+ visit than the HIV- men (29% [257/898] vs 21% [220/1,048], respectively; *p* < .001). Overall, 10% (1,116/10,571) of visits were FP+, and this proportion was also significantly higher in HIV+ than HIV- men (12% [601/4,842] vs 9% [515/5,729], respectively; *p* = .002). There were no significant differences by study site.

Among the 898 HIV+ men, those who were FP+ during at least one visit had a slightly lower median CD4 T-cell count, were slightly less likely to have a suppressed viral load, were twice as likely to have a history of AIDS, and had been receiving HAART for a year longer than those with no FP+ visits; all of these differences were statistically significant. In addition to having the same median number of completed study visits (median = 6, interquartile range: 4, 7), HIV+ and HIV- men also had similar proportions of FP+ study visits before September 2010 that were followed by one or more completed study visit before September 2011 (92% [384/417] and 90% [328/365], respectively; *p* = .29). The median number of completed study visits among men with zero FP+ study visits and at least one FP+ study visit was six (interquartile range: 4, 7). Thus, expression

Table 1. Characteristics of Men in the Multicenter AIDS Cohort Study, by Frailty Phenotype Expression, October 1, 2007 to September 30, 2011 (N = 1,946)

Characteristic*	Men Who Expressed the Frailty Phenotype N = 477		Men Who Did Not Express the Frailty Phenotype N = 1,469		p Value [†]
	n	%	n	%	
Median age (IQR)	53.8 (47.6, 61.3)		50.5 (44.6, 56.9)		<.001
Race					
Non-Hispanic white	275	58%	968	66%	<.001
Non-Hispanic black	150	31%	314	21%	
Hispanic	45	9%	164	11%	
Other	7	1%	23	2%	
Education					
≥college degree	192	40%	824	56%	<.001
HIV Status					
HIV uninfected	220	46%	828	56%	<.001
HIV infected	257	54%	641	44%	
<i>HIV-infected men only (N = 898)</i>					
Median CD4 count, cells/mm ³ (IQR)	512 (331, 642)		555 (396, 752)		.002
Median log ₁₀ HIV RNA, copies/mL (IQR)	1.6 (1.6, 2.0)		1.6 (1.6, 1.6)		.70
Undetectable plasma HIV RNA [‡]	176	71%	490	77%	.044
History of AIDS	63	25%	74	12%	<.001
Median number of years since AIDS diagnosis (IQR)	11.3 (5.5, 14.7)		10.2 (6.0, 13.0)		.86
Currently taking HAART	217	84%	539	84%	.90
Median number of years from HAART initiation (IQR)	10.7 (7.6, 12.2)		9.7 (6.1, 11.2)		<.001

Notes: HAART = highly active antiretroviral therapy; IQR = interquartile range. Bold values are statistically significant at $p < .05$.

*Characteristics measured at (a) the first visit where a participant met the frailty phenotype criteria or (b) the first visit attended between October 2007 and September 2011.

[†]p value calculated using a chi-square test statistic for a difference in proportions and the Kruskal–Wallis test for a difference in medians.

[‡]There were 14 men without a viral load measurement; thus, the percentages are calculated from a total of 884 men.

of the FP was not associated with differential follow-up by HIV status or FP status.

As expected, the proportion of FP+ visits increased with increasing age (Figure 1). This proportion was greater in HIV+ men for all age groups except for 45–49 years, and these differences were statistically significant for men aged 50–65 years. The intraclass correlation coefficients were 0.491 for HIV+ men and 0.579 for HIV– men, suggesting that a substantial proportion of the variability in expression of the FP was within men, similar to the level between men.

Among the 477 men who were ever FP+, 216 (45%) were FP+ at only one visit. Because the vast majority of these men completed six or more visits, as mentioned earlier, it can be inferred that FP+ expression was often transient (see Supplementary Appendix A). Of these 477 men, 293 (61%) had at least one subsequent FP– visit, 85 (18%) had only FP+ visits, and 99 (21%) were FP+ only at their last visit. Of the 10,276 consecutive visit pairs contributed by HIV+ and HIV– men, 5% (537) were classified as conversion and 4% (423) had an FP+ visit immediately followed by an FP– visit (ie, FP reversion); 5% (535) were FP+ at both visits, and 85% (8,772) were FP– at both visits.

To better understand the fluctuations in FP status and the higher prevalence of FP+ visits among HIV+ compared with HIV– men, predictors of conversion to the FP were examined.

Factors Related to Conversion to the FP (FP– to FP+)

This analysis was based on 9,309 (8,772 FP–, FP– and 537 FP–, FP+) consecutive visit pairs from 778 HIV+ and 935 HIV– men. Univariate and multivariate results are shown in Table 2. Overall, HIV infection was associated with a 46% increase in the odds of conversion in univariate models (odds ratio = 1.46 [1.18, 1.81]); HIV infection with and without AIDS was significantly associated with conversion (odds ratios relative to HIV– men = 2.56 [1.75, 3.75] and 1.31 [1.05, 1.64], respectively). In multivariate models, the association of HIV and AIDS status with conversion remained elevated but only HIV infection with AIDS was significant. Additionally, the odds of FP conversion increased with older age, non-Hispanic black race/ethnicity, cigarette smoking, hepatitis C infection, depressive symptoms, history of diabetes, and kidney disease, whereas the opposite was true for education to college or beyond (Table 2).

Multivariate models restricted to HIV+ men included 4,171 consecutive visit pairs (Table 2). Age, lower educational attainment, history of AIDS, depressive symptoms, diabetes, and kidney disease increased the odds of conversion; however, current and nadir CD4 T-cell counts did not. A test of interaction of age and HIV status (with and without AIDS) on FP+ study visits was not statistically significant ($p = .91$), suggesting that the relationship of age with conversion was not significantly different by HIV status.




Figure 1. The percent of study visits (and 95% confidence intervals) at which the criteria for the frailty phenotype were met, stratified by age and HIV status, October 1, 2007 to September 30, 2011, the Multicenter AIDS Cohort Study. * $p < .05$. Intraclass correlation coefficient: 0.491 for HIV-infected men; 0.579 for HIV-uninfected men.

Predictors of reversion from the FP (FP+ to FP− in consecutive study visits) were also examined and can be found in [Supplementary Appendix B](#).

Relationship Between Comorbidities and the FP

To better understand the relationship between comorbidities and HIV and AIDS status, we examined the prevalence of hepatitis C and age-related comorbidities measured at the first visit during the study period ($N = 1,496$). HIV+ men were more likely to have hepatitis C infection, depression, diabetes, and kidney disease and less likely to have high blood pressure, than HIV− men ([Table 3](#)). Dyslipidemia was the most common comorbidity in both HIV+ and HIV− men. HIV+ men also had a higher proportion with two or more comorbidities. Among men who were FP+ at their first study visit, 66% (62/94) of HIV+ men and 62% (48/78) of HIV− men had two or more comorbidities; these proportions did not differ dramatically in other study visits.

DISCUSSION

To our knowledge, this study is the first to evaluate the prevalence and expression of the FP defined and validated by Fried and colleagues (6,7), in HIV+ and similar HIV− MSM. Prevalence of the FP was higher in HIV+ compared with HIV− men, particularly in those aged 50 and older. We found substantial fluctuation in FP+ status in our study population. Examining factors associated with FP conversion allowed for consideration of this fluctuation. Concordance

of FP+ status and comorbidities was high, but a sizable proportion of HIV+ and HIV− men were FP+ with fewer than two comorbidities, suggesting that FP+ and comorbidities are not synonymous.

The FP+ prevalence of 12% among visits from HIV+ men in this study is similar to cross-sectional estimates in some studies, but not all. Other reported prevalences include 9% in a cohort with well-controlled HIV infection (41), 11% among HIV+ women in New York City (42), 5% in HIV+ women in the Women's Interagency HIV Study (43), 12.3% among injection drug users in the AIDS Link to the Intravenous Experience Study (44), and 19% in HIV+ adults in South Africa (45). All of these studies assessed the same FP used in this study, but differences in these study populations by age, sex, HIV transmission risk, underlying comorbidities, and severity and treatment of HIV disease likely account for the different prevalences of the FP. In the Cardiovascular Health Study, the population of presumably HIV−, aged 65 and older, community-dwelling adults in which the FP was developed, the prevalence of the FP was 7% (7). It is intriguing that the prevalence of the FP in much younger HIV− men in this study was higher (9%). Possible reasons for this unexpectedly high prevalence could include different lifestyles and exposures, or misclassification due to lack of validation of the FP phenotype in younger MSM. Further studies will be needed to address whether the definition of the FP needs to be modified for this population.

The prevalence of the FP increased with age in both HIV+ and HIV− men, as expected, but was higher in HIV+ men aged 50–64 years compared with HIV− men of the same age. These data should not be interpreted as evidence

Table 2. Univariate and multivariate (adjusted) odds ratios (OR and aOR, respectively) and 95% confidence intervals (95% CI) for conversion to the frailty phenotype (FP- to FP+), among men completing ≥ 2 visits, October 1, 2007 to September 30, 2011, the Multicenter AIDS Cohort Study ($N = 1,713$)

Predictor*	All Men (9,309 paired visits)		HIV-Infected Men (4,171 paired visits)	
	Univariate	Multivariate	Univariate	Multivariate
	OR (95% CI)	aOR (95% CI)	OR (95% CI)	aOR (95% CI)
Age (y)				
<40	0.78 (0.51, 1.19)	0.77 (0.49, 1.20)	0.73 (0.43, 1.24)	0.75 (0.43, 1.30)
40–44	0.99 (0.66, 1.47)	0.68 (0.45, 1.04)	0.68 (0.41, 1.11)	0.52 (0.31, 0.87)
45–49	0.95 (0.69, 1.32)	0.80 (0.56, 1.15)	0.74 (0.49, 1.12)	0.69 (0.44, 1.09)
50–54	1.00 (—)	1.00 (—)	1.00 (—)	1.00 (—)
55–59	1.12 (0.81, 1.54)	1.28 (0.92, 1.79)	1.03 (0.68, 1.55)	1.11 (0.72, 1.72)
60–64	1.20 (0.83, 1.73)	1.73 (1.18, 2.54)	1.24 (0.73, 2.10)	1.59 (0.90, 2.79)
≥ 65	2.11 (1.44, 3.02)	3.47 (2.28, 5.28)	1.25 (0.57, 2.73)	1.91 (0.85, 4.28)
Race/ethnicity				
Non-Hispanic white	1.00 (—)	1.00 (—)	1.00 (—)	1.00 (—)
Non-Hispanic black	1.87 (1.48, 2.36)	1.38 (1.03, 1.85)	1.59 (1.15, 2.21)	1.31 (0.89, 1.91)
Hispanic	0.12 (0.80, 1.66)	1.13 (0.76, 1.67)	1.18 (0.75, 1.83)	1.19 (0.75, 1.88)
Other	0.67 (0.28, 1.61)	0.67 (0.26, 1.73)	0.89 (0.31, 2.53)	0.76 (0.22, 2.58)
\geq College degree attained	0.56 (0.45, 0.69)	0.64 (0.50, 0.83)	0.58 (0.43, 0.80)	0.60 (0.43, 0.84)
Cigarette smoking	1.81 (1.46, 2.26)	1.46 (1.13, 1.89)	1.43 (1.06, 1.92)	1.19 (0.86, 1.65)
Injection drug use	0.63 (0.23, 1.76)		0.36 (0.09, 1.90)	
HIV and AIDS status				
HIV uninfected	1.00 (—)	1.00 (—)		
HIV infected, no history of AIDS	1.31 (1.05, 1.64)	1.26 (0.98, 1.64)	1.00 (—)	1.00 (—)
HIV infected, history of AIDS	2.56 (1.75, 3.75)	2.26 (1.50, 3.39)	1.96 (1.33, 2.87)	1.57 (1.06, 2.34)
Comorbidities [†]				
Hepatitis C infection	3.38 (2.44, 4.68)	1.66 (1.11, 2.49)	2.66 (1.77, 4.01)	1.48 (0.89, 2.47)
Depressive symptoms	2.83 (2.31, 3.47)	2.94 (2.35, 3.68)	2.82 (2.13, 3.72)	3.17 (2.35, 4.30)
High blood pressure	1.11 (0.88, 1.39)		0.83 (0.60, 1.16)	
History of diabetes	2.44 (1.84, 3.23)	1.74 (1.28, 2.38)	2.13 (1.44, 3.14)	1.87 (1.25, 2.80)
History of dyslipidemia	1.02 (0.79, 1.32)		0.82 (0.57, 1.18)	
Kidney disease	2.36 (1.85, 3.01)	1.53 (1.14, 2.05)	1.94 (1.43, 2.62)	1.46 (1.02, 2.08)
Liver disease	1.66 (0.79, 3.50)		1.53 (0.64, 3.66)	
Cancer	1.59 (0.70, 3.61)		2.36 (0.86, 6.50)	
<i>HIV-infected men only (n = 778)</i>				
CD4 count, cells/mm ³				
<200			1.88 (1.12, 3.16)	1.04 (0.59, 1.85)
200 to <350			1.68 (1.12, 2.52)	1.27 (0.81, 1.97)
350 to <500			1.28 (0.92, 1.79)	1.04 (0.73, 1.48)
≤ 500			1.00 (—)	1.00 (—)
Nadir CD4 count <200 cells/mm ³			1.72 (1.28, 2.32)	1.26 (0.90, 1.77)
Detectable plasma HIV RNA			1.21 (0.88, 1.67)	
HIV treatment				
No treatment			1.00	
Non-HAART regimen			1.34 (0.66, 2.73)	
Integrase inhibitor based			0.77 (0.47, 1.25)	
PI based			1.97 (0.94, 4.15)	
NNRTI based			1.41 (0.43, 4.60)	
PI and NNRTI based			0.52 (0.15, 1.79)	
NRTI based			1.06 (0.36, 3.15)	

Notes: HAART = highly active antiretroviral therapy; PI = protease inhibitor; NNRTI = nonnucleoside reverse transcriptase inhibitors; NRTI = nucleoside reverse transcriptase inhibitors. Bold values are statistically significant at $p < .05$.

*Predictors measured at the first visit of the pair, with the exception of (a) race and education, which were measured at entry into the Multicenter AIDS Cohort Study; (b) cigarette smoking, injection drug use, hepatitis C status, depressive symptoms, high blood pressure, diabetes, dyslipidemia, kidney disease, and liver disease, which were lagged one visit; and (c) cancer was self-reported at, or within a year of study visit. In addition to the predictors in the tables, the multivariate models were adjusted for the number of completed study visits (max = eight study visits).

[†]Depressive symptoms was measured as a Centers for Epidemiologic Studies Depression Scale score >16 . High blood was pressure measured as systolic >140 mmHg or diastolic >90 mmHg. Diabetes was measured as glucose >126 mg/dL or a self-report of previous clinical diagnosis. Dyslipidemia was measured as fasting total cholesterol ≥ 200 mg/dL or low-density lipoprotein ≥ 130 mg/dL or high-density lipoprotein <40 mg/dL or triglycerides ≥ 150 mg/dL or use of lipid-lowering medications with self-report of previous clinical diagnosis. Kidney disease measured as an estimated glomerular filtration rate <60 mL/min/1.73 m² body surface area (using the Modification of Diet in Renal Disease equation) or urine protein-to-creatinine ratio ≥ 200 .

Table 3. The prevalence of comorbidities at the first study visit, by HIV status, October 1, 2007 to September 30, 2011 the Multicenter AIDS Cohort Study ($N = 1,946$)

Comorbidity*	HIV infected	HIV uninfected	<i>p</i> Value [†]
	<i>N</i> = 898	<i>N</i> = 1,048	
	<i>n</i> (%)	<i>n</i> (%)	
Hepatitis C infection	88 (10)	51 (5)	<.001
Depressive symptoms	242 (27)	207 (20)	.002
High blood pressure	159 (18)	237 (23)	.012
History of diabetes	101 (11)	92 (9)	.015
History of dyslipidemia	664 (74)	690 (66)	<.001
Kidney disease	195 (22)	68 (6)	<.001
Liver disease	18 (2)	4 (0)	<.001
Cancer	4 (0)	17 (2)	.012
Multimorbidity			
0 comorbidities	100 (11)	203 (19)	<.001
1 comorbidity	355 (40)	479 (46)	
2 comorbidities	275 (31)	249 (24)	
3 comorbidities	120 (13)	83 (8)	
≥4 comorbidities	48 (5)	34 (3)	

Notes: Bold values are statistically significant at $p < .05$. *Comorbidity was measured at the first completed study visit. Hepatitis C infection was measured as the presence of hepatitis C RNA in serum. Depressive symptoms was measured as a Centers for Epidemiologic Studies Depression Scale score >16 . High blood was pressure measured as systolic >140 mmHg or diastolic >90 mmHg. Diabetes was measured as glucose >126 mg/dL or a self-report of previous clinical diagnosis. Dyslipidemia was measured as fasting total cholesterol ≥ 200 mg/dL or low-density lipoprotein ≥ 130 mg/dL or high-density lipoprotein <40 mg/dL or triglycerides ≥ 150 mg/dL or use of lipid-lowering medications with self-report of previous clinical diagnosis. Kidney disease was measured as an estimated glomerular filtration rate <60 mL/min/1.73 m² body surface area (using the Modification of Diet in Renal Disease equation) or urine protein to creatinine ratio ≥ 200 . Cancer was defined as self-reported diagnosis at, or within a year of, study visit.

[†]*p* Value was calculated using a chi-square test statistic.

of “accelerated” aging (46) for several reasons. First, this study did not define age at onset of the FP, only prevalence. Second, rates of comorbidities associated with expression of the FP were higher in HIV+ than HIV– men, as discussed later. Third, there was substantial fluctuation in expression of the FP, and it may not be valid to equate expression of the FP at just one study visit with the presence of frailty (or aging in general) in this population. Additional studies are needed to identify potential modifications to the FP to capture incident frailty events in this younger population of HIV+ and HIV– adults.

Conversion from FP– to FP+ status was significantly associated with the presence of conditions known to be associated with expression of the FP in elderly HIV– people (eg, depressive symptoms, diabetes, kidney disease, hepatitis C infection, and cigarette smoking). The fact that many factors and organ systems were associated with conversion suggests that expression of the FP is indicative of multisystem dysfunction in our study population, as it is in the older HIV– population. HIV infection, independent of these comorbidities, was significant only in the presence of a history of AIDS, suggesting that men who had AIDS before the introduction of HAART may have driven the association of HIV infection with expression of the FP. Median time from AIDS diagnosis did not differ, however, among HIV+ men with and without at least one FP+ visit. We did not see an independent association between lower CD4 T-cell count and FP+ status, as reported in other studies (27,43); this may be due to (a) collinearity due to the inclusion of comorbidities in

multivariate models, as this association was present in univariate models; and/or (b) the limited number of men with a very low CD4 T-cell count in this highly treated cohort. Due to this high level of treatment, the effect of HIV infection cannot be separated from that of HAART. Finally, having attained a college degree or beyond was significantly associated with a lower odds of frailty conversion, similar to cross-sectional studies of HIV+ adults in which frailty was associated with lower education attainment (44), unemployment (41), and homelessness (44). It is important to note that some of our null findings may be due to collinearity in the multivariate models, such as no difference in the odds of frailty conversion by race/ethnicity with the inclusion of education attained and no difference by nadir CD4 T-cell count with the inclusion of a history of clinical AIDS.

The previous cross-sectional studies of the FP in HIV+ populations could not assess fluctuation in FP status. One such study did reassess a small subset (7/100) of their study population 6 months after expressing the FP; one was still FP+, four were FP–, and two had died (47). In the present study, almost half of the men who expressed the FP did so at only one study visit over 4 years. The proportion of consecutive visit pairs in which reversion occurred was 4%. In a 4.5 year study of HIV– elderly people, the 18-month reversion rate ranged from 13%–24% in three 18-month periods (48). In the Women’s Health and Aging study, the rate ranged from 35%–85% in three 18-month periods (49). Finally, in a longitudinal study of the FP in HIV-infected and HIV-uninfected injection drug users, fluctuation in the

FP status was not assessed (44). It is difficult to compare these rates across studies because of the differences in outcome, study design, and sample size; most notably, our outcome was based on consecutive visit pairs, not individuals, and the studies among the elderly people had 18-month follow-up periods compared with our 6-month intervals. A recent qualitative study that aimed to create a framework for disability (an outcome linked to frailty in HIV-, older populations) in HIV+ adults described the disability experience as “episodic in nature” (50).

There was a greater prevalence of comorbidities (hepatitis C, depression, diabetes, and kidney disease) in HIV+ compared with HIV- men. Most men who were FP+ had two or more comorbidities at first visit in this study (66% of HIV+ and 62% of HIV- men). The proportions of men with the FP but less than two comorbidities (34% for HIV+ and 38% for HIV- men) were similar to that in the study population in which the FP was first described (30%) (7). These data suggest that comorbidities are potential etiologic agents for frailty, as hypothesized by Fried and colleagues (7), and also that the FP and comorbidities are not synonymous in either the present, younger HIV+ or the older HIV- population. An alternative interpretation is that the severity of comorbidities and unmeasured comorbidities not accounted for in this study could be contributing to the increased prevalence of FP expression. Further studies are needed to determine the relationship between the FP and comorbidities more precisely and whether comorbidities are etiologic agents of the FP in this younger, HIV+ population.

There are important limitations to this study. First, the FP has not been validated as a measure in HIV+ individuals, or in individuals aged 65 and younger. However, the FRP based on four of the five criteria used to define the FP was shown to predict AIDS-free survival in the MACS after initiation of HAART (28), and the FP predicted death in a cohort of HIV-infected and HIV-uninfected injection drug users (44), suggesting that the FP is likely to predict clinical outcomes in HIV+ people. Second, the MACS includes only men, so the present findings may not be generalizable to women. However, previous studies showed similar correlates of the FP in male-only (27) and female-only (43) populations, and expression of the FP predicted mortality in both HIV+ and HIV- people in a cohort of injection drug users that includes both men and women (44). Third, the variability in FP status and the brevity of the study period (4 years) complicate the interpretation of the FP in HIV+ adults and limit our ability to make causal inference regarding the relationship of HIV and FP. Despite these limitations, the MACS cohort is well suited to this question, due to the presence of an HIV- group that is similar to the HIV+ men (ie, the appropriate comparison group in which to study the effects of chronic HIV infection) and the large proportion of HIV+ men receiving HAART with suppression of HIV replication to undetectable levels, as would be

needed for long-term effects of HIV infection to become a possible health problem.

This study has contributed to a better understanding of the FP in treated HIV+ MSM by demonstrating measurement of the FP in a younger and HIV-infected population, quantifying the prevalence of and the fluctuation in FP+ status in HIV-infected MSM, determining the predictors of conversion to the FP+ status, and showing the degree of concordance of FP+ status and comorbidities. Nevertheless, our understanding of frailty in HIV+ adults is in its infancy. Modifications to the definition of frailty in younger, HIV+ adults are likely to be needed, such as requiring two consecutive study visits in which the FP is present. Though the clinical importance of the FP in elderly, HIV-uninfected adults is well established (6), its importance in HIV+ populations has not been well studied; however, evidence of its importance continues to emerge (44). Outcomes associated with the FP and mechanisms of frailty in HIV+ adults must be identified and articulated so that interventions can be developed to prevent it or lessen its impact. Ongoing follow-up of MSM in the MACS will continue to contribute to answering these questions and to understanding of the aging process among those living with HIV infection.

SUPPLEMENTARY MATERIAL

Supplementary material can be found at: <http://biomedgerontology.oxfordjournals.org/>

FUNDING

Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers at Baltimore (U01-AI35042): The Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (PI), Barbara Crain, Adrian Dobs, Homayoon Farzadegan, Joel Gallant, Lisette Johnson-Hill, Cynthia Munro, Michael W. Plankey, Ned Sacktor, Chloe Thio; Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University and Cook County Bureau of Health Services: Steven M. Wolinsky (PI), John P. Phair, Sheila Badri, Maurice O’Gorman, David Ostrow, Frank Palella, Ann Ragin; Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine: Roger Detels (PI), Otoniel Martínez-Maza (Co-PI), Aaron Aronow, Robert Bolan, Elizabeth Breen, Anthony Butch, Beth Jamieson, Eric N. Miller, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young, Zuo Feng Zhang; Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (PI), Lawrence A. Kingsley (Co-PI), James T. Becker, Ross D. Cranston, Jeremy J. Martinson, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall; and the Data Coordinating Center (UM1-AI35043): The Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (PI), Alvaro Munoz (Co-PI), Alison, Abraham, Keri Althoff, Christopher Cox, Jennifer Deal, Gypsyamber D’Souza, Priya Duggal, Janet Schollenberger, Eric C. Seaberg, Sol Su, Pamela Surkan. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR000424 (JHU CTSA). K.N.A. was supported by K01 AI093197 from the National Institute of Allergy and Infectious Diseases.

Website located at <http://www.statepi.jhsph.edu/macs/mac.html>. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH).

Meeting at which preliminary findings were presented: 3rd International Workshop on HIV & Aging, Baltimore, MD, Nov 2012.

ACKNOWLEDGMENTS

There are seven authors of this manuscript, all of whom have met the authorship credit criteria developed by the International Committee of Medical Journal Editors. More specifically: (a) Study concept and design: Althoff, Jacobson, Li, Margolick; (b) Acquisition of data: Cranston, Detels, Phair, Margolick; (c) Analysis and interpretation of data: Althoff, Jacobson, Li, Margolick; (d) Drafting of the manuscript: Althoff, Margolick; (e) Critical revision of the manuscript for important intellectual content: Althoff, Jacobson, Cranston, Detels, Phair, Li, Margolick. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the sponsors.

CONFLICTS OF INTEREST

No conflicts of interest are reported.

REFERENCES

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998;338:853–860.
2. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet*. 2008;372:293–299.
3. Prejean J, Song R, Hernandez A, et al. HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006–2009. *PLoS One*. 2011;6:e17502.
4. Centers for Disease Control and Prevention. *HIV Surveillance Report, 2009*. Atlanta, GA: Centers for Disease Control and Prevention; 2011:21.
5. Luther VP, Wilkin AM. HIV infection in older adults. *Clin Geriatr Med*. 2007;23:567–83, vii.
6. Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: characterization in the women's health and aging studies. *J Gerontol A Biol Sci Med Sci*. 2006;61:262–266.
7. Fried LP, Tangen CM, Walston J, et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56:M146–M156.
8. Fried LP, Walston J. Frailty and failure to thrive. In: Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander J, eds. *Principles of Geriatric Medicine and Gerontology*. New York: McGraw Hill; 1998. 1387–1402.
9. Lipsitz LA. Physiological complexity, aging, and the path to frailty. *Sci Aging Knowledge Environ*. 2004;2004:pe16.
10. Kang HG, Costa MD, Priplata AA, et al. Frailty and the degradation of complex balance dynamics during a dual-task protocol. *J Gerontol A Biol Sci Med Sci*. 2009;64:1304–1311.
11. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. *J Gerontol A Biol Sci Med Sci*. 2009;64:1049–1057.
12. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. *J Am Geriatr Soc*. 2006;54:991–1001.
13. Paganelli R, Di Iorio A, Cherubini A, et al. Frailty of older age: the role of the endocrine-immune interaction. *Curr Pharm Des*. 2006;12:3147–3159.
14. Bortz W. Understanding frailty. *J Gerontol A Biol Sci Med Sci*. 2010;65:255–6; discussion 257.
15. Fried LP, Hadley EC, Walston JD, et al. From bedside to bench: research agenda for frailty. *Sci Aging Knowledge Environ*. 2005;2005:pe24.
16. Klein BE, Klein R, Knudtson MD, Lee KE. Frailty, morbidity and survival. *Arch Gerontol Geriatr*. 2005;41:141–149.
17. Cawthon PM, Marshall LM, Michael Y, et al. Osteoporotic Fractures in Men Research Group. Frailty in older men: prevalence, progression, and relationship with mortality. *J Am Geriatr Soc*. 2007;55:1216–1223.
18. Woods NF, LaCroix AZ, Gray SL, et al. Women's Health Initiative. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. *J Am Geriatr Soc*. 2005;53:1321–1330.
19. Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syndrome. *Am J Med*. 2007;120:748–753.
20. Boyd CM, Xue QL, Simpson CF, Guralnik JM, Fried LP. Frailty, hospitalization, and progression of disability in a cohort of disabled older women. *Am J Med*. 2005;118:1225–1231.
21. Leone S, Gregis G, Quinzan G, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. *Infection*. 2011;39:13–20.
22. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS*. 2010;24:1537–1548.
23. Marin B, Thiébaud R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. *AIDS*. 2009;23:1743–1753.
24. Pacheco AG, Tuboi SH, May SB, et al. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. *J Acquir Immune Defic Syndr*. 2009;51:624–630.
25. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. *Ann Intern Med*. 2006;145:397–406.
26. Desquilbet L, Jacobson LP, Fried LP, et al. Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. *J Gerontol A Biol Sci Med Sci*. 2007;62:1279–1286.
27. Desquilbet L, Margolick JB, Fried LP, et al. Multicenter AIDS Cohort Study. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. *J Acquir Immune Defic Syndr*. 2009;50:299–306.
28. Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. *J Gerontol A Biol Sci Med Sci*. 2011;66:1030–1038.
29. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30:473–483.
30. Bing EG, Hays RD, Jacobson LP, et al. Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. *Qual Life Res*. 2000;9:55–63.
31. Radloff LS. A self-reported depression scale for research in the general population. *Appl Psychol Measurement*. 1997;1:385–401.
32. Jacobson LP, Phair JP, Yamashita TE. Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. *Curr Infect Dis Rep*. 2004;6:325–332.
33. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. *Am J Epidemiol*. 1987;126:310–318.
34. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multicenter AIDS Cohort Study: retention after 9 ½ years. *Am J Epidemiol*. 1995;142:323–330.
35. Detels R, Jacobson L, Margolick J, et al. The multicenter AIDS Cohort Study, 1983 to *Public Health*. 2012;126:196–198.
36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130:461–470.
37. Hultin LE, Menendez FA, Hultin PM, et al. Assessing immunophenotyping performance: proficiency-validation for adopting improved flow cytometry methods. *Cytometry B Clin Cytom*. 2007;72:249–255.

38. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. <http://aidsinfo.nih.gov/content-files/lvguidelines/adultandadolescentgl.pdf>. Accessed September 3, 2013.
39. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep*. 1992;41:1–19.
40. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*. 1986;42:121–130.
41. Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. *J Infect*. 2009;59:346–352.
42. Ferris D, Zhang C, Dam T, et al. Frailty rate in HIV+ mid-50 women matches rate in 70-year-olds without HIV. 6th IAS Conference on Pathogenesis, Treatment and Prevention, 2011.
43. Terzian AS, Holman S, Nathwani N, et al. Women's Interagency HIV Study. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. *J Womens Health (Larchmt)*. 2009;18:1965–1974.
44. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. *PLoS One*. 2013;8:e54910.
45. Pathai S, Gilbert C, Weiss HA, et al. Frailty in HIV-infected adults in South Africa. *J Acquir Immune Defic Syndr*. 2012;253:37–42.
46. Martin J, Volberding P. HIV and premature aging: A field still in its infancy. *Ann Intern Med*. 2010;153:477–479.
47. Ianas V, Berg E, Mohler MJ, Wendel C, Klotz SA. Antiretroviral therapy protects against frailty in HIV-1 infection. *J Int Assoc Provid AIDS Care*. 2013;12:62–66.
48. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. *Arch Intern Med*. 2006;166:418–423.
49. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med*. 2011;27:1–15.
50. Morgan EE, Iudicello JE, Weber E, et al. HIV Neurobehavioral Research Program (HNRP) Group. Synergistic effects of HIV infection and older age on daily functioning. *J Acquir Immune Defic Syndr*. 2012;61:341–348.